

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Carlyle Group Inc.</u> _____ (Last) (First) (Middle) C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVE. NW, SUITE 220S _____ (Street) WASHINGTON DC 20004-2505 _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/01/2022	3. Issuer Name and Ticker or Trading Symbol <u>SOLENO THERAPEUTICS INC [ SLNO ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	18,022,602	I	See footnotes <sup>(1)(2)(3)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(4)	12/21/2028	Common Stock	20,000	1.57	I	See footnotes <sup>(1)(2)(3)(5)</sup>
Stock Option (right to buy)	(6)	06/10/2029	Common Stock	12,357	2.5	I	See footnotes <sup>(1)(2)(3)(5)</sup>
Stock Option (right to buy)	(6)	05/18/2030	Common Stock	9,530	3.41	I	See footnotes <sup>(1)(2)(3)(5)</sup>
Stock Option (right to buy)	(6)	01/08/2031	Common Stock	40,000	2.24	I	See footnotes <sup>(1)(2)(3)(5)</sup>
Stock Option (right to buy)	(6)	06/01/2031	Common Stock	31,862	1.02	I	See footnotes <sup>(1)(2)(3)(5)</sup>
Warrants	(7)	03/29/2027	Common Stock	7,720,000	0.3	I	See footnotes <sup>(1)(2)(3)</sup>
Warrants	12/21/2018	12/21/2023	Common Stock	233,463	2	I	See footnotes <sup>(1)(2)(3)</sup>

1. Name and Address of Reporting Person* <u>Carlyle Group Inc.</u> _____ (Last) (First) (Middle) C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVE. NW, SUITE 220S _____ (Street) WASHINGTON DC 20004-2505 _____		
---	--	--

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[Carlyle Holdings I GP Inc.](#)

(Last) (First) (Middle)

C/O THE CARLYLE GROUP  
1001 PENNSYLVANIA AVE. NW, SUITE 220S

(Street)

WASHINGTON DC 20004-2505

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[Carlyle Holdings I GP Sub L.L.C.](#)

(Last) (First) (Middle)

C/O THE CARLYLE GROUP  
1001 PENNSYLVANIA AVE. NW, SUITE 220S

(Street)

WASHINGTON DC 20004-2505

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[Carlyle Holdings I L.P.](#)

(Last) (First) (Middle)

C/O THE CARLYLE GROUP  
1001 PENNSYLVANIA AVE. NW, SUITE 220S

(Street)

WASHINGTON DC 20004-2505

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[CG Subsidiary Holdings L.L.C.](#)

(Last) (First) (Middle)

C/O THE CARLYLE GROUP  
1001 PENNSYLVANIA AVE. NW, SUITE 220S

(Street)

WASHINGTON DC 20004-2505

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[TC Group, LLC](#)

(Last) (First) (Middle)

C/O THE CARLYLE GROUP  
1001 PENNSYLVANIA AVE. NW, SUITE 220S

(Street)

WASHINGTON DC 20004-2505

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

## Carlyle Investment Management LLC

(Last) (First) (Middle)

C/O THE CARLYLE GROUP

1001 PENNSYLVANIA AVE. NW, SUITE 220S

(Street)

WASHINGTON DC

20004-2505

(City)

(State)

(Zip)

### 1. Name and Address of Reporting Person\*

Carlyle Genesis UK LLC

(Last) (First) (Middle)

C/O THE CARLYLE GROUP

1001 PENNSYLVANIA AVE. NW, SUITE 220S

(Street)

WASHINGTON DC

20004-2505

(City)

(State)

(Zip)

### Explanation of Responses:

1. Reflects securities held of record by Abingworth Bioventures VII LP ("ABV VII"). ABV VII has delegated to Abingworth LLP ("Abingworth") all investment and dispositive power over the securities held of record by ABV VII.
2. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC (each of the foregoing entities, the "Carlyle Entities").
3. On August 1, 2022, entities affiliated with The Carlyle Group Inc. acquired Abingworth (the "Acquisition"). Following the Acquisition, Carlyle Genesis UK LLC became the principal member of Abingworth LLP. As a result, each of the Carlyle Entities may be deemed to have acquired beneficial ownership of the securities held of record by ABV VII or beneficially owned by Abingworth. Each of them disclaims beneficial ownership of such securities, except to the extent of their pecuniary interest therein.
4. The stock option will vest in 48 substantially equal monthly installments commencing on December 21, 2018.
5. Under an agreement between Andrew Sinclair and Abingworth, Dr. Sinclair is deemed to hold the stock option and any shares of Common Stock issuable upon exercise of the stock option for the benefit of ABV VII, and must exercise the stock option solely upon the direction of Abingworth.
6. The stock option is fully vested and exercisable.
7. The warrants contain a provision prohibiting exercise to the extent that the holder, together with its affiliates, would beneficially own in excess of 4.99% of the total number of shares of Common Stock then issued and outstanding.

### Remarks:

Following the Acquisition, the Carlyle Entities, ABV VII and Abingworth intend to file Section 16 reports jointly.

The Carlyle Group Inc.,  
By: /s/ Anne Frederick,  
Attorney-in-fact for Curtis L. Buser, Chief Financial  
Officer 08/11/2022

Carlyle Holdings I GP  
Inc., By: /s/ Anne  
Frederick, Attorney-in-fact  
for Curtis L. Buser,  
Managing Director and  
Chief Financial Officer 08/11/2022

Carlyle Holdings I GP Sub  
L.L.C., By: Carlyle  
Holdings I GP Inc., its sole  
member, By: /s/ Anne  
Frederick, Attorney-in-fact  
for Curtis L. Buser,  
Managing Director and  
Chief Financial Officer 08/11/2022

Carlyle Holdings I L.P.,  
By: /s/ Anne Frederick,  
Attorney-in-fact for Curtis  
L. Buser, Managing  
Director 08/11/2022

CG Subsidiary Holdings  
L.L.C., By: /s/ Anne  
Frederick, Attorney-in-fact 08/11/2022

